{"id":7992,"date":"2025-10-30T23:02:59","date_gmt":"2025-10-30T23:02:59","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/10\/30\/biotech-news-eli-lilly-surpasses-merck-pfifzer-novo-nordisk\/"},"modified":"2025-10-30T23:02:59","modified_gmt":"2025-10-30T23:02:59","slug":"biotech-news-eli-lilly-surpasses-merck-pfifzer-novo-nordisk","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/10\/30\/biotech-news-eli-lilly-surpasses-merck-pfifzer-novo-nordisk\/","title":{"rendered":"STAT+: Alnylam raises guidance as sales of heart drug match expectations"},"content":{"rendered":"<p>    STAT+: Alnylam raises guidance as sales of heart drug match expectations<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Morning! Today, we have a deep probe into Moderna\u2019s travails from STAT\u2019s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic\u00a0regulation, and the Trump administartion\u00a0is trying to fast-track cheaper biosimilars.\u00a0<\/p>\n<h2 class=\"wp-block-heading\" id=\"h-the-need-to-know-this-morning\">The need-to-know this morning<\/h2>\n<ul class=\"wp-block-list\">\n<li>\n<p>A new drug-sales king has been crowned. Eli Lilly\u2019s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro and Zepbound brand names, <a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-reports-third-quarter-2025-financial-results-highlights-rd\" rel=\"noopener\">delivered $10.1 billion<\/a> in third-quarter sales. Tirzepatide\u2019s quarterly sales surpassed the <a href=\"https:\/\/www.merck.com\/news\/merck-co-inc-rahway-n-j-usa-announces-third-quarter-2025-financial-results\/\" rel=\"noopener\">$8.1 billion in sales<\/a> from Merck\u2019s cancer immunotherapy blockbuster Keytruda for the first time.\u00a0<\/p>\n<\/li>\n<li>More earnings from <a href=\"https:\/\/news.bms.com\/news\/corporate-financial\/2025\/Bristol-Myers-Squibb-Reports-Third-Quarter-Financial-Results-for-2025\/default.aspx\" rel=\"noopener\"><strong>Bristol Myers Squibb<\/strong><\/a>, <a href=\"https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-reports-third-quarter-2025-results\" rel=\"noopener\">Biogen<\/a>, <a href=\"https:\/\/investor.insmed.com\/2025-10-30-Insmed-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update\" rel=\"noopener\">Insmed<\/a>, <a href=\"https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-pharmaceuticals-reports-third-quarter-2025-financial\" rel=\"noopener\">Apellis<\/a>, and <a href=\"https:\/\/newsroom.astellas.com\/2025-10-30-Financial-Results-of-Astellas-for-Q2-YTD-FY2025\" rel=\"noopener\">Astellas<\/a>.\u00a0<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\" id=\"h-moderna-s-mrna-empire-stumbles-amid-politics-retrenchment\">Moderna\u2019s mRNA empire stumbles amid politics, retrenchment<\/h2>\n<p>Once seemingly on top of the world, Moderna now faces a brutal reset.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/10\/30\/biotech-news-eli-lilly-surpasses-merck-pfifzer-novo-nordisk\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/10\/30\/biotech-news-eli-lilly-surpasses-merck-pfifzer-novo-nordisk\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Alnylam raises guidance as sales of heart drug match expectations Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Morning! Today, we have a deep probe into Moderna\u2019s travails from STAT\u2019s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic\u00a0regulation, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-7992","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7992"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7992"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7992\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}